PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Metformin

Drugs in development · updated 30 October 2026

Metformin: clinical trials and development status

Other names and codes: Riomet Er, Glumetza, Fortamet, Glucophage Xr

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 October 2003

As of 30 October 2026 Metformin is in 160 active clinical trials (recruiting or ongoing, phases I–III) for 141 diseases. The most advanced phase is III.

160Active trials
IIIMost advanced phase
141Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Metformin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 141 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Type 2 diabetesIII12NCT07026968
DiabetesIII8NCT05345327
Insulin resistanceIII8NCT04578652
ObesityIII7NCT07297290
Polycystic Ovary SyndromeIII4NCT07120815
Prostatic NeoplasmsII–III4NCT00268476
Cognitive dysfunctionIII3NCT05230758
Premature BirthIII3NCT06033131
Type-1 diabetesIII3NCT04583462
AtherosclerosisIII2NCT05132439
Chronic obstructive pulmonary diseaseIII2NCT06999343
InflammationIII2NCT04511416
Intraductal carcinoma of the breastIII2NCT01905046
Parkinson's diseaseIII2NCT07055958
Pre-eclampsiaIII2NCT06033131
Weight lossIII2NCT07297290
Autosomal dominant polycystic kidneyIII1NCT04939935
Birth weightIII1NCT06033131
Breast carcinoma in situIII1NCT01905046
Cerebrovascular diseaseIII1NCT04511416
Complications of pregnancyIII1NCT06452498
DementiaIII1NCT04511416
DyslipidemiaIII1NCT07045142
Experimental diabetes mellitusIII1NCT07279909
HELLP syndromeIII1NCT06452498
Idiopathic pulmonary fibrosisIII1NCT07520110
Intermittent claudicationIII1NCT05132439
MedulloblastomaIII1NCT05230758
Non-small-cell lung carcinomaIII1NCT05445791
Pediatric ObesityIII1NCT04578652

Everything on Metformin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch